160 related articles for article (PubMed ID: 8971561)
1. Immunohistochemical localization of Mcl-1 and bcl-2 proteins in thymic epithelial tumours.
Chen FF; Yan JJ; Chang KC; Lai WW; Chen RM; Jin YT
Histopathology; 1996 Dec; 29(6):541-7. PubMed ID: 8971561
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical staining for bcl-2 and mcl-1 in intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) and cervical thymic carcinoma.
Dorfman DM; Shahsafaei A; Miyauchi A
Mod Pathol; 1998 Oct; 11(10):989-94. PubMed ID: 9796728
[TBL] [Abstract][Full Text] [Related]
3. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours.
Pan CC; Chen PC; Wang LS; Lee JY; Chiang H
Histopathology; 2003 Aug; 43(2):165-72. PubMed ID: 12877732
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis, bcl-2 protein, and Fas antigen in thymic epithelial tumors.
Tateyama H; Eimoto T; Tada T; Inagaki H; Hattori H; Takino H
Mod Pathol; 1997 Oct; 10(10):983-91. PubMed ID: 9346177
[TBL] [Abstract][Full Text] [Related]
5. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
Kuo TT; Chan JK
Am J Surg Pathol; 1998 Dec; 22(12):1474-81. PubMed ID: 9850173
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas.
Stefanaki K; Rontogianni D; Kouvidou CH; Bolioti S; Delides G; Pantelidaki A; Sotsiou F; Kanavaros P
Histopathology; 1997 Jun; 30(6):549-55. PubMed ID: 9205859
[TBL] [Abstract][Full Text] [Related]
7. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.
Walts AE; Hiroshima K; Marchevsky AM
Ann Diagn Pathol; 2015 Aug; 19(4):216-20. PubMed ID: 25979154
[TBL] [Abstract][Full Text] [Related]
8. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms.
Datta MW; Shahsafaei A; Nadler LM; Freeman GJ; Dorfman DM
Appl Immunohistochem Mol Morphol; 2000 Sep; 8(3):210-5. PubMed ID: 10981873
[TBL] [Abstract][Full Text] [Related]
9. Thymic epithelial tumor progression in an SV40T transgenic mouse model. Cortical thymoma-thymic carcinoma sequence.
Lee SS; Park WY; Chi JG; Seo JW; Kim JI; Kim CW; Park SH; Khang SK; Cho KJ; Seo JS; Jang JJ
Virchows Arch; 1998 Jan; 432(1):33-42. PubMed ID: 9463585
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation in thymic epithelial tumors with special reference to thymic carcinoma and atypical thymoma.
Hishima T; Fukayama M; Hayashi Y; Fujii T; Arai K; Shiozawa Y; Funata N; Koike M
Hum Pathol; 1998 Apr; 29(4):330-8. PubMed ID: 9563781
[TBL] [Abstract][Full Text] [Related]
11. Proliferative activity and apoptosis in thymic epithelial neoplasms.
Hiroshima K; Iyoda A; Toyozaki T; Supriatna Y; Shibuya K; Shimamura F; Haga Y; Yoshida S; Fujisawa T; Ohwada H
Mod Pathol; 2002 Dec; 15(12):1326-32. PubMed ID: 12481014
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
[TBL] [Abstract][Full Text] [Related]
13. PE-35-related antigen expression and CD1a-positive lymphocytes in thymoma subtypes based on Müller-Hermelink classification. An immunohistochemical study using catalyzed signal amplification.
Hattori H; Tateyama H; Tada T; Saito Y; Yamakawa Y; Eimoto T
Virchows Arch; 2000 Jan; 436(1):20-7. PubMed ID: 10664158
[TBL] [Abstract][Full Text] [Related]
14. Expression of bcl-2 in fetal thymus, thymomas and thymic carcinomas. Association with p53 expression and review of the literature.
Engel P; Francis D; Graem N
APMIS; 1998 Apr; 106(4):449-55. PubMed ID: 9637266
[TBL] [Abstract][Full Text] [Related]
15. Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas.
Müller D; Mazzeo P; Koch R; Bösherz MS; Welter S; von Hammerstein-Equord A; Hinterthaner M; Cordes L; Belharazem D; Marx A; Ströbel P; Küffer S
BMC Med; 2021 Nov; 19(1):300. PubMed ID: 34781947
[TBL] [Abstract][Full Text] [Related]
16. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
17. Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness.
Chen FF; Yan JJ; Jin YT; Su IJ
Hum Pathol; 1996 Oct; 27(10):1089-92. PubMed ID: 8892596
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms.
Pomplun S; Wotherspoon AC; Shah G; Goldstraw P; Ladas G; Nicholson AG
Histopathology; 2002 Feb; 40(2):152-8. PubMed ID: 11952859
[TBL] [Abstract][Full Text] [Related]
19. Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity.
Dorfman DM; Shahsafaei A; Chan JK
Am J Surg Pathol; 1997 Aug; 21(8):936-40. PubMed ID: 9255257
[TBL] [Abstract][Full Text] [Related]
20. The potential role of bcl-2, bax, and Ki67 expression in thymus of patients with myasthenia gravis, and their correlation with clinicopathologic parameters.
Salakou S; Tsamandas AC; Bonikos DS; Papapetropoulos T; Dougenis D
Eur J Cardiothorac Surg; 2001 Oct; 20(4):712-21. PubMed ID: 11574213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
